目的 探讨他克莫司联合肾炎康复片治疗特发性膜性肾病（Idiopathic membranous nephropathy，IMN）的临床疗效。方法 选择2019年6月～2021年6月我院收治的80例IMN患者作为研究对象，将全部患者随机分为观察组和对照组各40例。对照组给予他克莫司治疗，观察组给予他克莫司联合肾炎康复片治疗，两组治疗疗程均为6个月。比较两组患者的缓解率，比较两组患者经治疗后的血清白蛋白和尿蛋白水平。比较两组治疗后炎症因子水平。比较两组患者的不良反应发生率。 结果 治疗2个月、3个月和6个月后，观察组的缓解率显著高于对照组（P＜0.05）。治疗3个月和6个月后，观察组的24h尿蛋白显著低于对照组，观察组的血白蛋白显著高于对照组。治疗后6个月，观察组的炎症因子水平显著低于对照组（P<0.05）。两组患者的各种不良反应发生率相比均无显著性差异。 结论 他克莫司联合肾炎康复片治疗IMN患者具有更优的临床疗效，且能降低炎症因子水平。

Objective To investigate the clinical efficacy of tacrolimus combined with Nephritis Rehabilitation Tablets in the treatment of Idiopathic membranous Nephropathy (IMN). Methods A total of 80 IMN patients admitted to our hospital from June 2019 to June 2021 were selected as the study subjects, and all patients were randomly divided into observation group and control group (40 cases in each group). The control group was given tacrolimus treatment, and the observation group was given tacrolimus combined with nephritis rehabilitation tablets. The treatment course of both groups was 6 months. The remission rate and serum albumin and urinary protein levels were compared between the two groups after treatment. The levels of inflammatory factors were compared between the two groups after treatment. The incidence of adverse reactions was compared between the two groups. Results After 2, 3 and 6 months of treatment, the remission rate in observation group was significantly higher than that in control group (P < 0.05). After 3 and 6 months of treatment, the 24h urinary protein in the observation group was significantly lower than that in the control group, and the blood albumin in the observation group was significantly higher than that in the control group. The level of inflammatory factors in the observation group were significantly lower than that in the control group at 6 months after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusions Tacrolimus combined with Nephritis Rehabilitation Tablets has better clinical efficacy in IMN patients and can reduce the level of inflammatory factors.